GLP-1 receptor agonists were evaluated for cardiovascular outcomes in patients with HFrEF and mitral regurgitation, but the abstract provides no specific results or conclusions.
Does GLP-1 RA therapy improve cardiovascular outcomes in patients with HFrEF and mitral regurgitation?
Absolute Event Rate: 0% vs 0%
Heart failure with reduced ejection fraction (HFrEF) and mitral regurgitation (MR) represent a high-risk population with significant morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular benefits in patients with diabetes and obesity. However, their impact on outcomes in patients with concomitant HFrEF and MR remains unclear. This study evaluated the association between GLP-1 RA therapy and cardiovascular outcomes in this high-risk population
Ottun et al. (Wed,) reported a other. GLP-1 receptor agonists were evaluated for cardiovascular outcomes in patients with HFrEF and mitral regurgitation, but the abstract provides no specific results or conclusions.